Chronic active lesions (‘smoldering’ spots) may be a hallmark for progressive forms of multiple sclerosis, a recently published study suggests.
Browsing: multiple sclerosis
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
MRI scans of individuals living with multiple sclerosis could predict how the disease will progress in the following years. This information could potentially be useful when considering treatment options.
A 65-year follow-up study of approximately 7000 multiple sclerosis patients has uncovered that overall, patients are 14% more likely to develop cancer compared to individuals without the disease.
A team of researchers have utilized radiocarbon dating to determine that there is little regeneration of oligodendrocytes in the brains of people living with multiple sclerosis. However, the oligodendrocytes that survive the autoimmune attack can replenish lost myelin.
In this research article from Biomarkers in Medicine, researchers determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis.
In this interview, we had the pleasure of speaking with Robert Fox about biomarker discovery and development in multiple sclerosis, including serum neurofilament light.
This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
The EMA has approved Gilenya® (fingolimod) for the treatment of children and adolescents with relapsing–remitting forms of multiple sclerosis.
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.